Brokerages Set MannKind Co. (NASDAQ:MNKD) PT at $9.56

MannKind Co. (NASDAQ:MNKD - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of analysts have recently commented on MNKD shares. Mizuho began coverage on MannKind in a research note on Thursday, April 10th. They issued an "outperform" rating and a $12.00 target price on the stock. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th. Finally, Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of MannKind in a research note on Thursday, February 27th.

Institutional Trading of MannKind

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in MannKind in the 4th quarter worth about $37,000. Jones Financial Companies Lllp boosted its stake in shares of MannKind by 3,294.8% in the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 6,392 shares during the last quarter. Blueshift Asset Management LLC purchased a new stake in shares of MannKind during the first quarter worth approximately $51,000. Sowell Financial Services LLC acquired a new position in MannKind in the 1st quarter valued at $56,000. Finally, Kovitz Investment Group Partners LLC purchased a new position in MannKind in the 4th quarter valued at $65,000. Hedge funds and other institutional investors own 49.55% of the company's stock.

MannKind Trading Down 0.9 %

NASDAQ MNKD traded down $0.04 on Monday, hitting $4.59. 447,037 shares of the company's stock traded hands, compared to its average volume of 1,984,830. The firm's 50-day moving average price is $4.90 and its two-hundred day moving average price is $5.84. The firm has a market capitalization of $1.39 billion, a PE ratio of 65.57 and a beta of 1.14. MannKind has a 1-year low of $4.22 and a 1-year high of $7.63.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. The company had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The firm's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 earnings per share. On average, research analysts anticipate that MannKind will post 0.1 earnings per share for the current fiscal year.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.